Natural Capsules Limited reported a consolidated net loss of ₹24.66 crore for the financial year ended March 31, 2026, compared to a net profit of ₹0.62 crore in the previous year. The loss was primarily attributed to the API segment, which reported a loss before tax and interest of ₹31.33 crore. For the quarter ended March 31, 2026, the company reported a net loss of ₹4.98 crore, while revenue from operations surged 55% to ₹58.45 crore, driven by the dispatch of deferred goods following the resumption of operations at the Puducherry plant.

The standalone financial performance for the year shows a net profit of ₹11.21 crore, a 67.1% year-on-year increase. Revenue from operations rose 3.5% to ₹173.77 crore. Earnings per share (EPS) on a basic basis improved to ₹10.79 from ₹6.43 in the prior year. The Board of Directors approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, at a meeting held on May 27, 2026. The company informed the exchanges that these audited results were published in Business Line and Sanjevani on May 29, 2026.

Financial Performance (Consolidated)

Financial Performance (Standalone)

Operational Updates

The Capsules segment remained profitable, reporting a profit before tax and interest of ₹20.82 crore. The company noted that the incremental HPMC line for double-zero capsules is ready, with revenue expected from the second half of FY27. On the API side, commercial sales commenced in Q4FY26. The subsidiary Natural Biogenex Private Limited executed agreements with Fermbox Bio Private Limited to utilise fermentation assets at the Tumkur facility, aiming to improve CDMO capabilities. The Board approved the re-appointment of Mr. Laxminarayan Moondra as Whole-Time Director for three years effective July 28, 2026, subject to shareholder approval.

Natural Capsules Limited has scheduled a conference call with investors and analysts to discuss its audited financial results for the fourth quarter and financial year ended March 31, 2026. The meeting is set to take place on Tuesday, June 2, 2026, at 4:00 PM IST. The discussion will focus on the company's performance for Q4 and FY26, along with its business outlook. The company confirmed that no price sensitive information will be disclosed during the call.

The announcement was made pursuant to Regulation 30 and Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was submitted to both BSE Limited and the National Stock Exchange of India Limited to ensure compliance with regulatory requirements.

Management Participants

The conference call will feature key members of the company's leadership team who will address queries regarding the financial results and future strategies.

Investors interested in participating can join via the provided toll-free numbers. Registration for the event is available through a dedicated link to facilitate access. For further information, stakeholders may contact the Investor Relations Advisor at TIL Advisors Private Limited.